Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ahmet Sevindik
In order to help curb the drugs bill, the Turkish Social Security Institution has decided to restrict the level of price increases that can be made on pharmaceutical products when the prices of those products are increased in reference or non-reference countries.
The general secretary of Turkey’s Association of Research based Pharmaceutical Companies (AIFD), Umit Dereli, tells the Pink Sheet why he thinks the government’s policy on local medicines production is wrong in terms of its scope, goal, and method.
Some 80 pharmaceutical and vitamin products already are available nonprescription in parts of Turkey, but a proposal in development for almost two years would be the country's first regulation for sales of consumer health care products.
Turkish drug industry association AIFD is demanding that the court cancels a government policy under which multinational companies are facing the threat of having their medicines removed from the reimbursement list unless they produce them locally.
The Turkish government plans to fix the country’s tamoxifen drug shortage problem by allowing by a local company to manufacture the product.
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.